Search

Tumor necrosis factor (TNF) inhibitors significantly improved the treatment options for patients with ankylosing spondylitis. Unfortunately, currently, there is no strategy for sustaining remission of the disease with TNF inhibitors; after discontinuation, a high percentage of patients experience flares in a short time. Therefore, up‐to‐date, long‐term use of TNF inhibitors in patients with ankylosing spondylitis remains necessary. For this reason, the issue of the long‐term safety of TNF inhibitors in patients with ankylosing spondylitis raises concerns. Although TNF inhibitors are well established in ankylosing spondylitis treatment, the majority of studies on TNF inhibitors' safety have been performed in patients with rheumatoid arthritis. Until recently, there were very few studies of TNF inhibitors' safety in ankylosing spondylitis. Meanwhile, TNF inhibitors appear to have different safety profiles in ankylosing spondylitis and rheumatoid arthritis. In this review, we describe available data on the occurrence of adverse events associated with TNF inhibitor treatment in ankylosing spondylitis, including serious adverse events, infections, serious infections, tuberculosis, opportunistic infections, hepatitis B reactivation, malignancies, laboratory test abnormalities, autoimmune diseases, paradoxical adverse events, and heart failure. [ABSTRACT FROM AUTHOR]

The need set by a computational industry to increase processing power, while simultaneously reducing the energy consumption of data centers, became a challenge for modern computational systems. In this work, we propose an optical communication solution, that could serve as a building block for future computing systems, due to its versatility. The solution arises from Landauer's principle and utilizes reversible logic, manifested as an optical logical gate with structured light, here represented as Laguerre-Gaussian modes. We introduced a phase-shift-based encoding technique and incorporated multi-valued logic in the form of a ternary numeral system to determine the similarity between two images through the free space communication protocol.

Introduction: Rheumatoid arthritis (RA) and periodontitis share risk factors and inflammatory pathways that could be related to cytokines, such as interleukin (IL)-6, IL-8, IL-17A, and tumour necrosis factor- α (TNF- α ). The aim of this study was to compare periodontal status and salivary levels of selected cytokines between patients diagnosed with RA and periodontitis. RA patients were assessed for the potential influence of anti-rheumatic therapy., Material and Methods: One hundred and six patients were enrolled in a cross-sectional study. Medical assessment and periodontal examination were performed in 35 patients with chronic periodontitis, in 35 patients with RA and chronic periodontitis, and in 36 controls. Unstimulated whole saliva samples were analysed for IL-6, IL-8, IL-17A, and TNF- α ., Results: Significant differences in biomarkers and periodontal parameters were found among groups. Study groups exhibited higher mean pocket depth (PD), number of PD > 4 mm, and mean clinical attachment loss, when compared with controls. The RA group had lower bleeding on probing index and PD, but higher values of plaque indices than the periodontitis group. Concentration of evaluated cytokines were higher in the RA and periodontitis groups, compared with controls. The periodontitis group showed also higher levels of IL-6, IL-17A, and TNF- α in comparison to RA. RA patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and glucocorticosteroids., Conclusions: Salivary levels of IL-6, IL-8, IL-17A, and TNF- α can be affected by periodontitis, RA, and presumably DMARDs. DMARD therapy appears to reduce destructive and inflammatory processes in periodontal tissues because lower values of PD, BOP, and salivary levels of IL-6, IL-17A, and TNF- α were found in RA., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2019 Polish Society of Experimental and Clinical Immunology.)

Objective: Cirrhotic cardiomyopathy is a chronic cardiac dysfunction in patients with liver cirrhosis. It is mostly characterized by impaired cardiac function, but some myocardial anatomical changes have also been described. The aim of this study was to assess the influence of liver cirrhosis on heart wall thickness changes in a retrospective pathological analysis of cirrhotic patients without hypertension., Materials and Methods: Statistical analysis of 11,860 autopsy protocols drawn up between 1981 and 2002 in the Department of Pathology Medical University of Warsaw was done., Results: Liver cirrhosis was confirmed by autopsy in 802 patients (6.7%); in 697 patients, hypertension was excluded. Analysis of heart wall thickness showed pathological changes in 53.2% of patients - left ventricular thickening in 9.3%, right ventricular thinning in 31.0%, and both in 12.9%. In clinical assessment, the cause of death in 25.8% of patients was cardiocirculatory failure, significantly more in the group with selective left ventricular thickening. It was the most common cause of death among them. Vascular changes in the upper gastrointestinal tract, liver enlargement and hepatic coma were also significantly related to the heart wall thickness changes occurrence., Conclusions: Based on statistical analysis of autopsy material, we concluded that liver cirrhosis can lead to heart wall thickness changes (left ventricular thickening and/or right ventricular thinning). We revealed that patients with selective left ventricular thickening had significantly more cardiac related causes of death. In clinical practice, treatment of cirrhotic cardiomyopathy requires specialized diagnostics and appropriate cardiological procedures involving the participation of a hepatologist, especially in the group of patients with selective left ventricular hypertrophy., (Copyright © 2014 Elsevier GmbH. All rights reserved.)